NEW YORK (GenomeWeb News) – Pacific Biosciences has filed for an initial public offering in the US, seeking to raise up to $200 million.
The Menlo Park, Calif.-based maker of a single-molecule, real-time sequencing (SMRT) technology platform, today filed a preliminary prospectus with the US Securities and Exchange Commission for the offering. It has not said how many shares that it intends to offer or when it anticipates the IPO will become effective
The filing comes only a month after Pacific Biosciences announced that it had raised $109 million in a Series F round of financing. The firm has raised around $370 million since its inception through private financings.
PacBio said that it intends to use proceeds from the offering for ongoing R&D associated with the SMRT technology, to increase sales and marketing efforts in advance of its intended commercial launch of the system later this year, to increase the scale of its manufacturing operations, and for general corporate purposes including hiring personnel.
For the year ended Dec. 31, 2009, PacBio brought in revenues of $135,000 and posted a net loss of $87.7 million, or $86.52 per share. For the six months ended June 30, 2010, it generated revenues of $1.2 million and a net loss of $63 million, or $49.79 per share.
As of June 30, PacBio held $138.8 million in cash, cash equivalents, and investments.
Underwriters for the offering include JP Morgan, Morgan Stanley, Deutsche Bank, and Piper Jaffray.
PacBio's IPO filing comes only two weeks after another sequencing firm, Complete Genomics, filed to go public. Complete Genomics said in its filing that it hopes to raise as much as $86.3 million.